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Diet-induced obesity alters dural CGRP
release and potentiates TRPA1-mediated
trigeminovascular responses
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Abstract
Background: Clinical studies suggest a link between obesity and the primary headache disorder migraine. In our study
we aimed to reveal the effect of obesity on meningeal nociceptor function in rats receiving a high-fat, high-sucrose diet.
Methods: Transient receptor potential ankyrin 1 (TRPA1) receptor activation-induced changes in meningeal blood flow,
release of calcitonin gene-related peptide (CGRP) from trigeminal afferents and TRPA1 protein expression in the
trigeminal ganglia were measured in control and obese rats. Metabolic parameters of the animals were assessed by
measuring glucose and insulin homeostasis as well as plasma cytokine concentrations.
Results: The present experiments revealed an enhanced basal and TRPA1 receptor agonist-induced CGRP release from
meningeal afferents of obese insulin-resistant rats and an attenuated CGRP release to potassium chloride. Obesity was
also associated with an augmented vasodilatation in meningeal arteries after dural application of the TRPA1 agonist
acrolein, a reduction in TRPA1 protein expression in the trigeminal ganglia and elevations in circulating proinflammatory
cytokines IL-1b and IL-6 in addition to increased fasting blood glucose and insulin concentrations.
Conclusions: Our results suggest trigeminal sensitisation as a mechanism for enhanced headache susceptibility in obese
individuals after chemical exposure of trigeminal nociceptors.
Keywords
Obesity, calcitonin gene-related peptide, sensory neuron, laser Doppler flowmetry, headache, transient receptor
potential ankyrin 1
Date received: 9 February 2016; revised: 30 April 2016; accepted: 23 May 2016
Introduction
Obesity is one of the most signiﬁcant global health
issues. Clinical and population-based studies suggest a
link between obesity and the common and disabling
primary headache disorder migraine. Obesity may
enhance the frequency and severity of headache attacks
and appears to increase the risk for having migraine (1).
Experimental results indicate multiple areas of overlap
between migraine pathophysiology and the mechanisms
related to excess body fat (2,3). Adipose tissue has sig-
niﬁcant endocrine functions by producing bioactive
molecules that serve as regulators of metabolism and
also possess immunoregulatory functions (4–6).
Primary headaches are associated with increased
activity of the trigeminal nociceptive pathway (7).
Earlier studies revealed that chemosensitive neurons
expressing members of the transient receptor potential
(TRP) receptor family play a crucial role in nociception
and neurogenic vascular reactions in diﬀerent tissues
including the meninges (8–10). Activation of trigeminal
chemosensitive aﬀerents that innervate the dura mater
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facilitates pain signalling towards the central nervous
system and elicits the release of neuropeptides, such as
calcitonin gene-related peptide (CGRP) and substance P
(SP), from their peripheral terminals leading to arterial
vasodilatation, increase in vascular permeability and
degranulation of mast cells (7). Peripheral events follow-
ing the activation of dural chemosensitive nociceptors
may generate positive feedback reactions that augment
the initial vascular and nociceptive responses (11).
Enhanced activation of the trigeminovascular noci-
ceptive pathway may result from sensitisation of men-
ingeal nociceptors by cytokines and other inﬂammatory
mediators. They have been shown to aﬀect ion channels
expressed in peripheral endings of trigeminal nocicep-
tors, leading to increased excitability and sensitisation
(12). Prolonged activation of meningeal primary aﬀer-
ents may also sensitise second-order neurons of the
nociceptive pathway in the caudal trigeminal nucleus.
Central sensitisation is considered a signiﬁcant patho-
physiological mechanism in the development of pri-
mary headaches (13).
The signiﬁcance of CGRP in the pathophysiology of
migraine is among the most widely discussed topics in
the ﬁeld of headache research (14). Clinical and experi-
mental observations indicate a possible link between
migraine and TRPA1 receptor activation-dependent
release of CGRP from trigeminovascular nociceptive
aﬀerents. Further, activation of nasal mucosal trigem-
inal aﬀerents which express the TRPA1 receptor has
been suggested as a pathophysiological mechanism
involved in the generation of headache induced by
inhaled environmental irritants (15). The TRPA1 agon-
ist acrolein is a component of tobacco smoke, vehicle
exhaust and vapours of overheated cooking oils, which
along with other TRPA1 agonists are known triggers of
migraine attacks in susceptible individuals (16,17).
Importantly, prolonged exposure to acrolein through
inhalation has been demonstrated to sensitise the trige-
minovascular system (18).
Obesity is often associated with chronic low-grade
systemic inﬂammation characterised by enhanced
levels of proinﬂammatory cytokines, reactive oxygen
and nitrogen species (4,19,20). TRPA1 channels are
potential targets of these agents. Modiﬁcation of the
TRPA1 receptor function leading to enhanced activity
of the trigeminal nociceptors may be the mechanism
underlying the activation of the nociceptive pathway
and changes in meningeal blood ﬂow in headache
patients (16).
Although the aetiology of obesity is multifactorial,
the Western-type diet is considered as a major contribu-
tor to the obesity pandemic (21). Therefore, animal
models of diet-induced obesity are widely accepted
approaches to mimic and, in turn, study human obesity
and associated pathophysiological disturbances (22).
The present experiments were initiated in an attempt
to reveal the eﬀects of obesity on the TRPA1 receptor-
mediated meningeal nociceptor function in rats main-
tained on a high-fat, high-sucrose (HFHS) diet. We
measured, therefore, TRPA1 activation-induced changes
in meningeal blood ﬂow, CGRP release from trigeminal
aﬀerents and TRPA1 protein expression in trigeminal
ganglia of control and obese animals. Metabolism was
also assessed by examining glucose and insulin homeo-
stasis as well as plasma cytokine concentrations.
Materials and methods
Animals and diet
Experiments were approved by the Ethical Committee
for Animal Care of the University of Szeged and the
University of Debrecen. Study procedures were car-
ried out in accordance with the Directive 2010/63/
EU of the European Parliament. All eﬀorts were
made to minimise the number of animals used and
their suﬀering.
Male Sprague Dawley rats initially weighing 150–170g
(6 weeks old) were housed in an environmentally con-
trolled room (12-hour light/dark cycle, 22 2C, 50%–
70% relative humidity) and randomly divided into two
groups. The control group was maintained on a regular
diet consisting of standard laboratory chow (3.20kcal/g,
59% carbohydrate, 32% protein, 9% fat; diet
code: S8106-S011 SM R/M-ZþH, ssniﬀ Spezialdia¨ten
GmbH, Germany) and tap water. The experimental
group received an HFHS diet composed of high-fat
chow (4.56kcal/g, 35% carbohydrate, 20% protein,
45% fat; diet code: 824018, Special Diets Services, UK)
and tap water containing 5% sucrose. Diets were
provided ad libitum for 20 weeks. All experiments were
performed at the end of the dietary treatment period in
26-week-old animals when body weight (BW) was also
measured.
Assessment of insulin sensitivity
The hyperinsulinaemic euglycaemic glucose clamp
(HEGC) method was used to estimate insulin resistance
by measuring the amount of glucose necessary to main-
tain normoglycaemia in the presence of increased insulin
levels during a steady-state condition (23).
After an overnight fast, rats were anesthetised with
thiopental sodium (100mg/kg, intraperitoneally (i.p.))
and the trachea was cannulated to allow free breathing.
The left and right jugular veins were cannulated for
insulin (Humulin R, Eli Lilly, Indianapolis, IN, USA)
and glucose (20%) infusion administered by means of
an infusion pump. Blood sampling and monitoring of
mean arterial pressure were performed through a
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cannula inserted into the right carotid artery. The body
temperature of the rats was kept at 37.0–37.5C. After a
short stabilisation period, a continuous insulin infusion
was commenced at a rate of 3 mU/kg/minutes (min)
over 120min during which the blood glucose was main-
tained at a euglycaemic level (5.5 0.5mmol/l) by
adjusting the rate of glucose infusion. Blood glucose
concentration was determined at 10-min intervals
using a glucometer (Accu-Chek, Roche Diagnostics,
Budao¨rs, Hungary). Steady-state condition was deﬁned
when the blood glucose level had stabilised for at least
20min. In order to determine plasma insulin concentra-
tion, arterial blood samples were taken before the start
of insulin infusion and during the steady-state period.
Blood samples were centrifuged for 2min at 4C and
10,000 g, and the plasma was aliquoted, frozen and
stored at 70C for later analysis. The average glucose
infusion rate (GIR, mg/kg/min) needed to maintain
euglycaemia during the steady state condition was
used to characterise whole-body insulin sensitivity (24).
A homeostasis model assessment of insulin resist-
ance (HOMA-IR) was calculated by using the data
on fasting blood glucose (FBG, mmol/l) and fasting
plasma insulin (FPI, mU/ml) levels obtained from the
HEGC study as well as from a separate set of experi-
ments aimed to determine circulating levels of plasma
biomarkers. HOMA-IR was established as the product
of FBG and FPI divided by a constant of 22.5 (25).
Analysis of plasma biomarkers (FBG, insulin,
tumour necrosis factor  (TNF), interleukin
(IL)-1 and IL-6)
A separate set of experiments was performed to measure
FBG, plasma insulin, TNFa, IL-1b and IL-6 concentra-
tions. Overnight fasted rats were anesthetised with thiopen-
tal sodium (100mg/kg, i.p.) and a cannula was placed into
the carotid artery for blood sampling. After a short stabil-
isation period, blood glucose was determined by means of
a glucometer, and blood samples were taken in Eppendorf
cups. Samples were processed and stored as described
above. Insulin concentrations of plasma samples, including
those that were collected during the HEGC study, were
determined by immunoradiometric assay (IRMA) using
a commercially available insulin IRMA kit (Institute of
Isotopes, Budapest, Hungary). TNFa, IL-1b (Thermo
Scientiﬁc, Waltham, MA, USA, each) and IL-6 (Life
Technologies, Carlsbad, CA, USA) were measured by
enzyme-linked immunoassay (EIA) according to the manu-
facturer’s instructions.
Measurement of adiposity
The group of rats used for the assessment of meta-
bolic parameters was also used later for the
measurement of adiposity. After completing the
experiments, intra-abdominal and epididymal white
adipose tissue (WAT) fat pads were removed and
weighed. Adiposity was characterised by expressing
the sum of the WAT fat pads as a percentage of total
BW.
In vivo recordings of meningeal blood flow
Changes in meningeal blood ﬂow were measured in
an open cranial window model (26). Control and
obese rats were anesthetised with thiopental sodium
(150mg/kg, i.p.) and the trachea was cannulated to
allow spontaneous breathing. Systemic blood pres-
sure was recorded with a pressure transducer con-
nected to a cannula inserted into the femoral artery.
The body temperature was monitored by a rectal
thermoprobe and was kept at 37–37.5C with a heat-
ing pad. The head of the rats was stabilised in a
stereotaxic frame and a cranial window was made
into the parietal bone by means of a saline-cooled
drill to expose the dura mater (8,26). Blood ﬂow
was recorded with a needle-type probe of a laser
Doppler ﬂowmeter (Perimed, Sweden) positioned
over a branch of the middle meningeal artery lying
distant from visible cortical blood vessels. Blood ﬂow
was measured in perfusion units (PU). Data on men-
ingeal blood ﬂow and systemic blood pressure were
processed with the Perisoft program (Perimed,
Sweden). Stimulation of the dura mater was per-
formed by topical application of acrolein (50, 100
and 300 mM), CGRP and histamine (both 100 mM)
at a volume of 40 ml for 5min followed by repeated
washouts with synthetic interstitial ﬂuid (SIF, con-
taining in mM: 135NaCl, 5KCl, 1MgCl2, 5 CaCl2,
10 glucose and 10 Hepes, pH 7.4) between them. In
control rats the eﬀects of pretreatments with the
TRPA1 receptor antagonist HC-030031 (50 mM) and
the CGRP receptor antagonist CGRP8–37 (100 mM)
on acrolein-induced (300 mM) blood ﬂow increase
also were tested. Both antagonists were topically
applied for 5min prior to stimulation with acrolein
(300 mM). HC-030031 was purchased from Tocris,
Bristol, UK (stored as a 10mM stock solution
in dimethyl sulfoxide (DMSO)); all other drugs
were from Sigma-Aldrich Chemie Gmbh (Germany)
and were dissolved in SIF immediately before use.
Basal blood ﬂow was determined as the mean ﬂow
during 5min prior to drug application. Percentage
changes in meningeal blood ﬂow in response to
drug application were determined by comparing
basal ﬂow with the mean value of 1min where
change in blood ﬂow was maximal within the 5-min
application period.
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In vitro measurement of CGRP release
An in vitro rat dura mater preparation was used to
assess basal and stimulated release of CGRP (27).
Control and obese rats were decapitated following
deep anaesthesia with thiopental sodium (150mg/kg
i.p.). The skull was divided into halves along the mid-
line after the removal of the skin and muscles. The
cerebral hemispheres were removed, skull halves were
washed at room temperature for 30min in carbogen-
gassed SIF, then settled in a humid chamber and the
cranial fossae were ﬁlled with 300 ml SIF. Samples of
the superfusate were collected with a micropipette at
periods of 5min for CGRP measurement. A control
sample was taken after two consecutive washouts
with SIF in order to determine basal CGRP release,
then the dura was stimulated with acrolein at concen-
trations of 10, 50, 100 or 300 mM. In some control
experiments the eﬀect of the TRPA1 receptor antagon-
ist HC-030031 (50 mM) pretreatment on acrolein-
induced (300 mM) CGRP release was also measured.
In the other skull half the eﬀect of KCl (60mM) appli-
cation was compared with basal CGRP release.
A total of 100 ml of samples diluted with 25 ml EIA
buﬀer were placed into Eppendorf cups and immedi-
ately frozen at –70C for subsequent analysis. The EIA
method was used for CGRP determination (Bertin
Pharma, France). The CGRP concentrations of the
superfusates were expressed in pg/ml. Changes induced
in CGRP release by acrolein and KCl were expressed as
percentage changes relative to the basal release.
Measurement of TRPA1 protein expression
in the trigeminal ganglion
Western blot analysis was used to determine TRPA1
protein expression in the trigeminal ganglia.
Overnight fasted rats were anesthetised with thiopental
sodium (150mg/kg, i.p.) and decapitated. Trigeminal
ganglia were removed and homogenised in ice-cold
NP40 buﬀer (Thermo Fisher Scientiﬁc, Rockford, IL,
USA) supplemented with 1mM phenylmethylsulfonyl
ﬂuoride and protease inhibitor cocktail (both Sigma-
Aldrich, St. Louis, MO, USA). Homogenates were
sonicated twice for 10 seconds (sec) each and agitated
constantly for two hours at 4C. Lysates were centri-
fuged for 20min at 13,680 g at 4C. The protein concen-
tration of the supernatant was determined by BCA
Protein Assay (Thermo Fisher Scientiﬁc, Rockford, IL,
USA). Whole-cell lysates (40-50mg protein) were ana-
lysed on 10% sodium dodecyl sulphate (SDS) polyacryl-
amide gel under reducing conditions. Immunoblotting
was carried out on a nitrocellulose membrane using a
rabbit anti-TRPA1 antibody (1:2500, Alomone Labs,
Jerusalem, Israel) together with b-actin (1:1000, Cell
Signalling Technology, Danvers, MA, USA) overnight
at 4C followed by incubation with donkey anti-rabbit
immunoglobulin (Ig)G-horseradish peroxidase (HRP)
(1:5000, Santa Cruz Biotechnology, Dallas, TX, USA)
for an hour at room temperature. Immunoreactive
bands were visualised by the SuperSignal West Pico
Chemiluminescent Substrate (Thermo Fisher Scientiﬁc,
Rockford, IL, USA) using a Gel Logic 1500 Imaging
System (Kodak, Tokyo, Japan).
Statistics
All values were expressed as meansSEM. Statistical
analysis of the data was performed using Statistica 12
(StatSoft, Tulsa, OK, USA). For the statistical com-
parisons of CGRP and cytokine concentrations, men-
ingeal blood ﬂow changes and TRPA1 protein
expression the Student’s t test was used for group
sizes of n 10 and the Mann-Whitney U test for inde-
pendent measurements of group sizes n< 10. One-way
analysis of variance (ANOVA) followed by the
Bonferroni test was used to compare metabolic param-
eters of the animals. A probability level of p< 0.05 was
regarded as statistically signiﬁcant.
Results
Effect of HFHS diet on BW, adiposity
and metabolic parameters
During the 20 weeks of the dietary treatment period,
rats fed with an HFHS diet gained signiﬁcantly more
weight than the controls. Terminal BWs were 600 14g
in control and 745 17g in obese animals (p< 0.001).
The obese group had a signiﬁcantly greater amount of
intra-abdominal (p< 0.001) and epididymal WAT
(p< 0.001) along with a higher WAT to BW ratio
(p< 0.001) compared to the control group (n¼ 14 for
both groups; Table 1).
In obese rats signiﬁcant elevations in FBG
(p¼ 0.044) and insulin concentrations (p< 0.001) were
measured accompanied by a signiﬁcant increase in
HOMA-IR index (p< 0.001, n¼ 14 for both groups)
and a decreased GIR value (p¼ 0.028, n¼ 5 for both
groups; Table 2).
HFHS diet inﬂuenced diﬀerentially plasma cytokine
levels. In obese animals signiﬁcantly higher concentra-
tions of IL-1b (p¼ 0.011) and IL-6 (p< 0.001) were mea-
sured, whereas TNFa levels were similar in control and
obese rats (n¼ 9 for both groups, p¼ 0.26; Figure 1).
Diet-induced obesity potentiates increases
in meningeal blood flow elicited by acrolein
Basal blood ﬂow measured in PU depends critically on
the size of the arteries over which the probes of the laser
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Doppler ﬂowmeter are positioned. In our experimental
settings, therefore, we have carefully chosen identical
segments of the medial meningeal artery for the blood
ﬂow measurements. The basal ﬂow values were in the
same range in control and obese rats amounting to
226.1 20.2 and 214.4 20.1 PU (p¼ 0.96), respect-
ively. Topical administration of drugs activating
TRPA1 receptors of trigeminal aﬀerents (acrolein), or
acting directly on endothelial- or smooth muscle cells of
blood vessels (histamine and CGRP) increased menin-
geal blood ﬂow both in control and obese rats. The
maximal increase in blood ﬂow could be observed gen-
erally in the third, and in a few cases in the fourth min
of the 5-min drug application period independently of
the type of stimulating agent.
Systemic blood pressure was slightly above the
values measured earlier in non-obese animals under
the same experimental conditions (8). It was 128 17
and 134 13mmHg in control and obese rats, respect-
ively. Drugs administered topically to the dura mater
failed to inﬂuence systemic blood pressure.
In control rats acrolein induced a dose-dependent
increase in meningeal blood ﬂow that was signiﬁcantly
diﬀerent from the controls at 100 (n¼ 10; p< 0.001)
and 300 mM (n¼ 12; p< 0.001) concentrations. The
blood ﬂow-increasing eﬀect of acrolein at 300mM was
abolished by the pretreatment of the dura mater with
the TRPA1- (n¼ 8; p¼ 0.001) and CGRP receptor
antagonists (n¼ 8; p¼ 0.001, Figure 2).
Dural administration of acrolein resulted in signiﬁ-
cantly higher increases in maximal meningeal blood
ﬂow in obese animals (control n¼ 10, obese n¼ 9;
p¼ 0.049). Histamine- and CGRP-induced increases
in meningeal blood ﬂow were similar in control (n¼ 6
and 5, respectively) and obese rats (n¼ 7 and 6; p¼ 0.29
and 0.53, respectively, Figure 2).
Diet-induced obesity enhances basal
and acrolein-stimulated CGRP release
and attenuates the response to KCl
In the ex vivo dura mater preparation the basal release
of CGRP was 16.03 1.59 in control and 40.23
6.2 pg/ml in obese rats (p< 0.001). These data indicate
a signiﬁcantly increased spontaneous basal CGRP
release in obese animals. Acrolein at a concentration
of 10 and 50 mM failed to inﬂuence CGRP release in
control animals (n¼ 7 and n¼ 6, p¼ 0.88 and p¼ 0.203,
respectively). Acrolein at 10 mM concentration was also
ineﬀective in obese animals (n¼ 7, p¼ 0.51). Higher
concentrations of acrolein (100 and 300mM) signiﬁ-
cantly increased the release of CGRP (control: n¼ 8,
p< 0.001 for both acrolein concentrations; obese:
n¼ 14, p¼ 0.001 for 100 mM). Acrolein-induced
CGRP release was inhibited by pretreatment with the
TRPA1 antagonist (n¼ 8, p¼ 0.001). Obese rats
released signiﬁcantly more CGRP as compared with
the control group (p¼ 0.039, Figure 3).
KCl (60mM) increased CGRP release to 307.4
38.3% (n¼ 8, p< 0.001) and 182.7 18.2% (n¼ 13,
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Figure 1. Effect of diet-induced obesity on plasma concentra-
tions of tumour necrosis factor a (TNFa), interleukin-1b (IL-1b)
and interleukin-6 (IL-6). The number of experiments is indicated
in the bars. *Statistically different from the control.
Table 2. Effect of diet-induced obesity on fasting blood glucose
(FBG) and fasting plasma insulin (FPI) concentrations, homeo-
stasis model assessment of insulin resistance (HOMA-IR) index
and glucose infusion rate (GIR) of the animals.
FBG FPI HOMA-IR GIR
(mmol/l) (mU/ml) (mg/kg/min)
Control 5.54 0.2 18.38 1.93 4.48 0.47 9.66 1.35
(n: 14) (n: 14) (n: 14) (n: 5)
Obese 6.16 0.22a 39.59 4.55a 11.12 1.49a 4.6 1.34a
(n: 14) (n: 14) (n: 14) (n: 5)
p¼ 0.044 p< 0.001 p< 0.001 p¼ 0.028
aStatistically different from controls.
Table 1. Effect of high-fat, high-sucrose diet on the amount of
intra-abdominal and epididymal fat pads and the ratio of white
adipose tissue to body weight (WAT/BW).
Intra-abdominal
fat (g)
Epididymal
fat (g)
WAT/BW
(%)
Control (n: 14) 10.1 3.4 12.5 3.3 3.9 0.8
Obese (n: 14) 27.0 9.3a 23.6 5.9a 7.4 1.4a
p< 0.001 p< 0.001 p< 0.001
aStatistically different from controls.
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p< 0.001) in control and obese animals, respectively.
Although depolarisation-induced increase in CGRP
release was signiﬁcantly diﬀerent from basal values in
both groups, the high potassium-induced release was
signiﬁcantly lower in the obese rats as compared with
the controls (p¼ 0.001, Figure 3).
Diet-induced obesity reduces TRPA1 protein
expression in the trigeminal ganglia
The TRPA1 antibody detected a band at 110 kDa from
whole-cell lysates of rat trigeminal ganglia. Following
incubation of anti-TRPA1 antibody with its cognate pep-
tide provided by the manufacturer, the band could no
longer be detected indicating the speciﬁcity of the antibody
for the TRPA1 protein. There was a signiﬁcant reduction
in the expression of this 110kDa protein in the trigeminal
ganglia of obese rats compared with the control group
(control: n¼ 7, obese: n¼ 8, p¼ 0.048, Figure 4).
Discussion
The present study was initiated in an attempt to reveal
possible mechanisms through which metabolic changes
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Figure 2. Changes in acrolein-, histamine- and calcitonin gene-related peptide (CGRP)-induced increases in meningeal blood flow. (a)
Original recordings and (b) statistical evaluation indicating the maximal blood flow-increasing effects of topical applications of acrolein (50,
100 and 300mM), histamine, CGRP (both 100mM) and effects of TRPA1- (HC-030031, 50mM) and CGRP receptor antagonist (CGRP8–
37, 100mM) on acrolein (300mM)-induced meningeal vasodilatation. The number of experiments is indicated in the bars. *Statistically
different from the basal flow, #Statistically different from the effect of acrolein at 300mM, zStatistically different from controls.
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may aﬀect the trigeminovascular system resulting in
disturbances of trigeminal sensory functions, in particu-
lar the sensation of intracranial pain. Therefore,
the eﬀects of HFHS diet-induced obesity was studied
on the trigeminovascular system by combining well-
established methods of experimental headache research
with measurements of metabolic parameters and
plasma levels of inﬂammatory cytokines.
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Rats maintained on an HFHS diet exhibited elevated
FBG and insulin levels resulting in a signiﬁcant increase
in HOMA-IR index and a decreased GIR. Impairments
in glucose and insulin homeostasis were associated with
increased plasma levels of IL-1b and IL-6 (28).
Sensory neurogenic vascular reactions of dural blood
vessels are reliable indicators of the eﬀerent, local vascu-
lar functions of chemosensitive aﬀerent nerves serving the
dura mater (8,26,29). In the present study, administration
of acrolein, a TRPA1 receptor agonist, resulted in an
increase in meningeal blood ﬂow that was inhibited by
pretreatment of the dura mater with the TRPA1- or
CGRP receptor antagonist, suggesting an activation of
peptidergic meningeal chemosensitive aﬀerent nerves.
In vitro experiments furnished direct evidence for the
release of CGRP by acrolein. These observations provide
further support for acrolein, a common environmental
pollutant, being an agonist on TRPA1 receptors of men-
ingeal aﬀerents initiating increases in dural blood ﬂow
implicated in the mechanism of intracranial pain
(11,30). Probably the most intriguing ﬁnding of the pre-
sent study was that, in obese animals, in comparison with
the controls, dural application of acrolein resulted in sig-
niﬁcantly increased elevations of meningeal blood ﬂow.
In accord with this ﬁnding, acrolein-evoked in vitro
release of CGRP was signiﬁcantly increased in obese ani-
mals. Interestingly, in obese rats, the basal release of
CGRP was also elevated. The meningeal vasodilatory
eﬀects of histamine and CGRP, which act directly on
their endothelial and vascular smooth muscle receptors,
were similar in control and obese animals.
In obese rats the markedly elevated levels of circulat-
ing IL-1b and IL-6 indicate a systemic inﬂammatory
condition of the animals (4). These cytokines may acti-
vate and sensitise trigeminal aﬀerents in multiple ways
such as altering the expression and/or modifying the
gating properties of ion channels (31). In vivo electro-
physiological recordings demonstrated that both IL-1b
and IL-6 can increase the excitability of meningeal
nociceptors (32,33). IL-1b has been found to stimulate
cyclooxygenase-2 and prostaglandin E2 synthesis as
well as the release of CGRP in cultured trigeminal gan-
glion neurons (34). Inﬂammatory soup consisting of
prostaglandin E2, bradykinin and histamine profoundly
aﬀects the electrophysiological properties of dural aﬀer-
ents leading to a decrease in the activation threshold
and an increase in ﬁring rate (35). Inﬂammatory soup
has been shown to depolarise the resting membrane
potential of meningeal aﬀerents (31). IL-1b was able
to exert similar eﬀect in small trigeminal nociceptive
neurons through the inactivation of voltage-gated
potassium channels (36). Change in resting membrane
potential is considered an important mechanism under-
lying the sensitisation of dural aﬀerents evoked by
inﬂammatory mediators leading to increased basal
CGRP release (31). CGRP release induced by high KCl
concentration requires the opening of voltage-gated cal-
cium channels (37). The activity and/or expression of
these channels may also be inﬂuenced by persistently
elevated IL-1b and IL-6 levels possibly contributing to
reduced CGRP release upon neuronal depolarisation
with KCl (38). The IL-1b-induced increase in cyclooxy-
genase-2 activity, however, may result in the production
of a variety of electrophilic molecules that can potentially
modulate TRPA1 function (39,40). Our ﬁndings on
unchanged levels of plasma TNFa in obese rats are in
line with several reports showing that diet-induced obes-
ity may increase TNFa concentration in the adipose and
muscle tissue, but it does not necessarily lead to increased
plasma levels of TNFa (41,42).
Although this aspect was not speciﬁcally investigated,
oxidative and nitrosative stress may also modulate the
observed neurovascular reactions in obese animals.
Oxidative stress has been found to be increased in the
nervous system of diet-induced obese mice that was cor-
related with the amount of adipose tissue (43). In our
study, obese rats had signiﬁcantly higher FBG concen-
trations accompanied by a marked hyperinsulinaemia
whereas insulin resistance was also conﬁrmed by
increased HOMA-IR index and lower GIR value (44).
High-fat diet-induced obesity with reduced glucose tol-
erance and elevated insulin levels has been shown to be
associated with the accumulation of 4-hydroxynonenal
(4-HNE), an important biomarker of lipid peroxidation,
in primary sensory neurons (45). 4-HNE can selectively
activate TRPA1 resulting in enhanced excitability of che-
mosensitive nociceptors and release of CGRP (46).
Since in HFHS obese rats impaired glucose and insu-
lin homeostasis and increased levels of IL-1b and IL-6
were observed, it is reasonable to assume that changes
in basal and stimulated CGRP release can be the ﬁnal
outcomes of intricate dose- and time-dependent inter-
actions of the above factors resulting in sensitisation of
dural aﬀerents. This assumption is in line with previous
ﬁndings showing an enhanced activity of the trigeminal
pain pathway in obese mice (47,48).
Channel sensitisation, increased traﬃcking and/or
membrane expression of the receptors are possible mech-
anisms of nociceptor sensitisation. Although data about
the exact mechanisms of cytokine-induced sensitisation
of TRPA1 receptors are sparse, knowledge concerning
the cytokine eﬀects on another member of the TRP
receptor family, the transient receptor potential vanilloid
1 (TRPV1) receptor, which is highly colocalised with
TRPA1 in dural aﬀerents (49), may be relevant.
Indeed, an increased traﬃcking of both TRPV1 and
TRPA1 receptors induced by TNFa has been demon-
strated in trigeminal neurons (50), while IL-1b and
bradykinin sensitised TRPV1 receptor without increas-
ing its membrane expression (51). Since in our obesity
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model an increase in plasma IL-1b concentration
was associated with an unaltered TNFa level and a
slightly reduced TRPA1 receptor expression, the
augmented neurovascular responses following TRPA1
activation may be attributed to channel sensitisation
rather than an altered expression and/or traﬃcking of
the receptor.
TRPA1-immunoreactive perivascular axons form
bundles in the dura mater (30), in which the exact
number of immunoreactive aﬀerents cannot be reliably
determined. Therefore we applied the Western blot tech-
nique to provide (semi)quantitative data on the density of
meningeal TRPA1 receptors. The reduced TRPA1 pro-
tein expression in the trigeminal ganglia of obese rats can
be considered part of compensatory mechanisms due to
persistently increased neuronal activity (52).
Recent ﬁndings have shown that collaterals of che-
mosensitive meningeal nociceptors project through the
skull, innervate extracranial tissues, e.g. nasal mucosa,
forming functional connections between extra- and
intracranial structures (53). Sensitised TRPA1 channels
of trigeminal aﬀerents innervating the nasal mucosa are
targets of inhaled irritants, such as acrolein, and their
stimulation may lead to enhanced activity of the trige-
minovascular nociceptive pathway in obese animals,
and probably in humans.
In conclusion, this study demonstrates that HFHS-
diet-induced obesity leads to the sensitisation of dural
aﬀerents and, consequently, increased neural and vascu-
lar responses in the trigeminovascular system upon
TRPA1 activation. The ﬁndings may also bear relevance
with respect to pathologies relating to obesity and envir-
onmental pollutants. First, an increased incidence of
migraine headache is well documented in obese individ-
uals (1). Second, several environmental pollutants have
been shown to produce headache through activation of
the TRPA1 receptor (54). The present study, by reveal-
ing changes in metabolic homeostasis, plasma cytokine
levels and, in particular, sensitisation of TRPA1 recep-
tors expressed by trigeminovascular aﬀerents, provides
novel insight into possible mechanism of headaches
induced by environmental pollutants.
Article highlights
. Diet-induced obesity leads to sensitisation of meningeal trigeminovascular aﬀerents.
. Enhanced activity of the nociceptive pathway through obesity-induced sensitisation of trigeminal transient
receptor potential ankyrin 1 (TRPA1) receptors may promote headache generation.
. Obesity-induced sensitisation of TRPA1 receptors is likely the result of altered gating properties of the
receptor channel.
. Obesity increases basal and TRPA1 receptor-mediated release of calcitonin gene-related peptide (CGRP)
from trigeminovascular aﬀerents.
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